Ancora Advisors’s Enliven Therapeutics ELVN Stock Holding History

Ancora Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-28	Closed	–	–	2265
2022 Q1	$0	Buy	+28	New	+$185	﹤0.01%	2443

Other funds holding ELVN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ancora Advisors's ELVN Position: Q2 2022 in Review

Ancora Advisors sold out of Enliven Therapeutics (ELVN) in Q2 2022, closing a stake of 28 shares.

Ancora Advisors first reported a position in ELVN in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 26 funds tracked by Wall St. Rank hold ELVN as of Q2 2022.

Ancora Advisors reported no remaining Enliven Therapeutics position as of Q2 2022 after selling out during the quarter.
Ancora Advisors sold 28 Enliven Therapeutics shares in Q2 2022.
Ancora Advisors first reported a position in Enliven Therapeutics in Q1 2022 and held it in 1 quarter.
Ancora Advisors's Enliven Therapeutics position peaked at $0 in Q1 2022.
26 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2022.

Based on Ancora Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.